Pregnant women and infants are at risk should they contract mpox but there are no approved vaccines for this population.

Results from this study could support an extension of the current approval of MVA-BN to include children from 2 years of age ...

The World Health Organization said on Monday, October 14 that it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to ...

COPENHAGEN, Denmark, October 29, 2024 - Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a clinical study of the MVA-BN ® mpox/smallpox vaccine in children 2 to 11 years of age.

Bavarian Nordic is looking to expand the approval label of its MVA-BN mpox/smallpox vaccine to include children two to 11 years of age and has started a Phase II trial to support the approval.

The registrational trial is expected to support the Bavarian’s mpox/smallpox vaccine use in children between 2 and 11 years ...

The WHO declared mpox a global public health emergency for the second time in two years in August after a new variant of the ...

Bavarian Nordic gets $63 million US government order for small pox, mpox vaccine September 24, 2024 Future of Healthcategory Bavarian says mpox vaccine approved by EU regulator for adolescents ...

The World Health Organization said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks of the ...